

## Annual General Meeting – Conference Link

PYC Therapeutics (ASX:PYC) (PYC or the Company) reminds shareholders that the Annual General Meeting of the Company (AGM) will be held on Wednesday 23 November 2022 at 10.00am AWST. The AGM will be held at the Auditorium, The Harry Perkins Institute of Medical Research, QEII Medical Centre, 6 Verdun Street, Nedlands, Western Australia.

**PYC invites all shareholders to join the Company's Annual General Meeting commencing at 10am AWST (1pm AEDST) on Wednesday 23 November 2022 by registering on the following zoom link:**

Register in advance for this meeting:

[https://us02web.zoom.us/joining/register/tZYrceivrzkue9cjDFTIXO-d6u\\_ARivqcebY](https://us02web.zoom.us/joining/register/tZYrceivrzkue9cjDFTIXO-d6u_ARivqcebY)

After registering, you will receive a confirmation email containing information about joining the meeting.

### About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a pre-clinical stage biotechnology company pioneering a new generation of RNA therapeutics that utilise PYC's proprietary library of naturally derived cell penetrating peptides to overcome the major challenges of current genetic medicines. PYC believes its PPMO (Peptide conjugated Phosphorodiamidate Morpholino Oligomer) technology enables a safer and more effective RNA therapeutic to address the underlying drivers of a range of genetic diseases for which no treatment solutions exist today. The Company is leveraging its leading-edge science to develop a pipeline of novel therapies including three preclinical stage programs focused on inherited eye diseases and a preclinical discovery program focused on neurodegenerative diseases. PYC's discovery and laboratory operations are located in Australia, and its preclinical, clinical and regulatory operations are performed in the U.S. For more information, visit [pyctx.com](http://pyctx.com), or follow us on [LinkedIn](#) and [Twitter](#).

### Forward looking statements

*Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes*

*no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.*

*This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.*

*This ASX announcement was approved and authorised for release by the CEO of PYC Therapeutics Limited*

## **CONTACTS:**

### **INVESTORS**

info@pyctx.com

### **MEDIA**

info@pyctx.com